Pancreatic Cancer Research

ResearcherPhilipps University of MarburgActive in the last 2 years

Bert A. Bonsing

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4513-5737; OpenAlex author ID A5052876669, A5110950823. Sources: OpenAlex.

Their work

Papers
128 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
254
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 2 papers · 2014: 4 papers · 2015: 3 papers · 2016: 8 papers · 2017: 7 papers · 2018: 6 papers · 2019: 8 papers · 2020: 13 papers · 2021: 10 papers · 2022: 14 papers · 2023: 17 papers · 2024: 12 papers · 2025: 12 papers · 2026: 11 papers

Papers 50 of 128

  1. Pancreatic cancer risk and survival in patients with Lynch syndrome: a nationwide Dutch cohort study. Co-author DOI 10.1016/j.eclinm.2026.103755↗
  2. The impact of age on quality of life, 90-day mortality, adjuvant chemotherapy, and survival after treatment for localized pancreatic cancer: A nationwide analy… Co-author DOI 10.1016/j.ejca.2026.116822↗
  3. Survival benefit of recurrence-focused treatment after surgery for pancreatic ductal adenocarcinoma: A propensity score matched analysis of patients from a Dut… Co-author DOI 10.1016/j.ejca.2026.117776↗
  4. Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis. Co-author DOI 10.1016/j.ejso.2025.111165↗
  5. Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide population-based analysis. Co-author DOI 10.1016/j.hpb.2025.12.035↗
  6. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  7. Continuity of care experienced by patients diagnosed with pancreatic cancer: nationwide multicentre study. Co-author DOI 10.1093/bjsopen/zrag033↗
  8. Staging Laparoscopy After Neoadjuvant Treatment for Pancreatic Cancer to Prevent Non-Therapeutic Laparotomy: Analysis in the PREOPANC-2 Randomized Trial. Co-author DOI 10.1097/sla.0000000000007025↗
  9. Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial. Co-author DOI 10.1200/jco-25-01935↗
  10. Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18639-1↗
  11. ASO Visual Abstract: Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18791-8↗
  12. Pancreatic cancer surveillance not recommended for familial adenomatous polyposis: a fine and gray risk analysis. Co-author DOI 10.1007/s10689-025-00512-5↗
  13. Both skeletal muscle index and muscle attenuation are associated with frailty in preoperative older patients with pancreatic cancer. Co-author DOI 10.1016/j.clnu.2025.11.004↗
  14. 10-year survival after resection of pancreatic ductal adenocarcinoma with pathological re-examination of a nationwide cohort. Co-author DOI 10.1016/j.ejca.2025.116099↗
  15. Tumor gene expression is associated with venous thromboembolism in patients with ductal pancreatic adenocarcinoma. Co-author DOI 10.1016/j.thromres.2024.109240↗
  16. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multice… Co-author DOI 10.1016/s1470-2045(25)00363-8↗
  17. Resectability stages of pancreatic cancer: nationwide reference. Co-author DOI 10.1093/bjs/znaf120↗
  18. Delayed gastric emptying after pancreatic cancer surgery impacts time to start of adjuvant treatment but not overall survival: a post-hoc analysis of the PREOP… Co-author DOI 10.1093/bjs/znaf261↗
  19. Routine Imaging After Resection of Pancreatic Ductal Adenocarcinoma: Nationwide Utilization and Survival Analysis. Co-author DOI 10.1097/sla.0000000000006772↗
  20. Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled Trial. Co-author DOI 10.1097/sla.0000000000006910↗
  21. Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol. Co-author DOI 10.1186/s12885-025-13554-w↗
  22. Patient preferences for pancreatic cancer treatment (PERSEUS): a multicenter discrete choice experiment. Co-author DOI 10.1186/s12955-025-02440-5↗
  23. Computer-Aided Decision Support and 3D Models in Pancreatic Cancer Surgery: A Pilot Study. Co-author DOI 10.3390/jcm14051567↗
  24. Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2023.7872↗
  25. Aspects and outcomes of surveillance for individuals at high-risk of pancreatic cancer. Co-author DOI 10.1007/s10689-024-00368-1↗
  26. Screening for pancreatic cancer in high-risk individuals using MRI: optimization of scan techniques to detect small lesions. Co-author DOI 10.1007/s10689-024-00394-z↗
  27. Preoperative chemoradiotherapy but not chemotherapy is associated with reduced risk of postoperative pancreatic fistula after pancreatoduodenectomy for pancrea… Co-author DOI 10.1016/j.surg.2024.01.029↗
  28. Metformin boosts antitumor immunity and improves prognosis in upfront resected pancreatic cancer: an observational study. Co-author DOI 10.1093/jnci/djae070↗
  29. The Added Value of Blood Glucose Monitoring in High-Risk Individuals Undergoing Pancreatic Cancer Surveillance. Co-author DOI 10.1097/mpa.0000000000002335↗
  30. Predicting Long-term Disease-free Survival After Resection of Pancreatic Ductal Adenocarcinoma: A Nationwide Cohort Study. Co-author DOI 10.1097/sla.0000000000006004↗
  31. Nationwide Use and Outcome of Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy. Co-author DOI 10.1245/s10434-023-14650-6↗
  32. ASO Author Reflections: Nationwide Experience on Locally Advanced Pancreatic Cancer Surgery After Induction Chemotherapy in the Netherlands: A Stepping Stone f… Co-author DOI 10.1245/s10434-023-14704-9↗
  33. The Value of Biological and Conditional Factors for Staging of Patients with Resectable Pancreatic Cancer Undergoing Upfront Resection: A Nationwide Analysis. Co-author DOI 10.1245/s10434-024-15070-w↗
  34. Prediction of Isolated Local Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Nationwide Study. Co-author DOI 10.1245/s10434-024-15664-4↗
  35. The Difficulty of Detecting Occult Metastases in Patients with Potentially Resectable Pancreatic Cancer: Development and External Validation of a Preoperative … Co-author DOI 10.3390/jcm13061679↗
  36. Serum levels of iCAF-derived osteoglycin predict favorable outcome in pancreatic cancer. Co-author DOI 10.1002/ijc.34276↗
  37. Prediction of Biomarker Expression on Primary Pancreatic Ductal Adenocarcinoma Tissues Using Fine-Needle Biopsies: Paving the Way for a Patient-Tailored Molecu… Co-author DOI 10.1007/s40291-022-00635-w↗
  38. The yield of staging laparoscopy for resectable and borderline resectable pancreatic cancer in the PREOPANC randomized controlled trial. Co-author DOI 10.1016/j.ejso.2022.12.011↗
  39. Diagnostic performance of endoscopic tissue acquisition for pancreatic ductal adenocarcinoma in the PREOPANC and PREOPANC-2 trials. Co-author DOI 10.1016/j.hpb.2023.04.018↗
  40. Nationwide evaluation of pancreatic cancer networks ten years after the centralization of pancreatic surgery. Co-author DOI 10.1016/j.hpb.2023.07.904↗
  41. Feasibility, safety, and efficacy of stereotactic body radiotherapy combined with intradermal heat-killed mycobacterium obuense (IMM-101) vaccination for non-p… Co-author DOI 10.1016/j.radonc.2023.109541↗
  42. Practice variation in venous resection during pancreatoduodenectomy for pancreatic cancer: A nationwide cohort study. Co-author DOI 10.1016/j.surg.2023.06.012↗
  43. Surveillance for Pancreatic Cancer in High-Risk Individuals Leads to Improved Outcomes: A Propensity Score-Matched Analysis. Co-author DOI 10.1053/j.gastro.2023.02.032↗
  44. Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderl… Co-author DOI 10.1093/bjs/znad210↗
  45. Impact of complications after resection of pancreatic cancer on disease recurrence and survival, and mediation effect of adjuvant chemotherapy: nationwide, obs… Co-author DOI 10.1093/bjsopen/zrac174↗
  46. Outcome of Pancreatic Surgery During the First 6 Years of a Mandatory Audit Within the Dutch Pancreatic Cancer Group. Co-author DOI 10.1097/sla.0000000000005628↗
  47. Increasing Systemic Immune-inflammation Index During Treatment in Patients With Advanced Pancreatic Cancer is Associated With Poor Survival: A Retrospective, M… Co-author DOI 10.1097/sla.0000000000005865↗
  48. Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial. Co-author DOI 10.1186/s12885-023-11141-5↗
  49. Intraoperative Ultrasound During Surgical Exploration in Patients with Pancreatic Cancer and Vascular Involvement (ULTRAPANC): A Prospective Multicenter Study. Co-author DOI 10.1245/s10434-023-13112-3↗
  50. Nationwide Impact of Centralization, Neoadjuvant Therapy, Minimally Invasive Surgery, and Standardized Pathology Reporting on R0 Resection and Overall Survival… Co-author DOI 10.1245/s10434-023-13465-9↗

Closest collaborators

The 25 strongest of 254 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marc G. Besselink · 64 shared papers, 2014–2026 · strength 8.35
  2. Bas Groot Koerkamp · 53 shared papers, 2017–2026 · strength 6.89
  3. Ignace H. J. T. de Hingh · 51 shared papers, 2014–2026 · strength 6.70
  4. Hjalmar C. van Santvoort · 39 shared papers, 2014–2026 · strength 5.21
  5. Izaak Quintus Molenaar · 41 shared papers, 2014–2026 · strength 5.09
  6. J. Sven D. Mieog · 39 shared papers, 2014–2025 · strength 4.67
  7. Casper H.J. van Eijck · 41 shared papers, 2014–2026 · strength 4.59
  8. Vincent Erwin de Meijer · 30 shared papers, 2020–2026 · strength 4.52
  9. Johanna W. Wilmink · 29 shared papers, 2018–2026 · strength 3.94
  10. Martijn W.J. Stommel · 26 shared papers, 2020–2026 · strength 3.78
  11. Marjolein Y.V. Homs · 24 shared papers, 2020–2026 · strength 3.61
  12. Judith de Vos‐Geelen · 25 shared papers, 2016–2026 · strength 3.50
  13. Sebastiaan Festen · 24 shared papers, 2016–2026 · strength 3.40
  14. Alexander L. Vahrmeijer · 30 shared papers, 2014–2025 · strength 3.23
  15. Lois A. Daamen · 18 shared papers, 2021–2026 · strength 2.76
  16. Geert Kazemier M · 19 shared papers, 2016–2026 · strength 2.51
  17. Martijn Intven · 16 shared papers, 2021–2026 · strength 2.47
  18. Geertjan van Tienhoven · 20 shared papers, 2014–2026 · strength 2.42
  19. Vincent B. Nieuwenhuijs · 17 shared papers, 2020–2026 · strength 2.37
  20. Jeanin Elise van Hooft · 14 shared papers, 2020–2026 · strength 2.19
  21. Gijs A. Patijn · 17 shared papers, 2016–2026 · strength 2.07
  22. Lydia G. van der Geest · 15 shared papers, 2018–2026 · strength 2.05
  23. Robert C. Verdonk · 12 shared papers, 2022–2026 · strength 1.95
  24. Hanneke W.M. van Laarhoven · 14 shared papers, 2018–2026 · strength 1.89
  25. Martin N.J.M. Wasser · 15 shared papers, 2011–2024 · strength 1.68

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.